AstraZeneca reports that its late-stage clinical trial of Wainua, a treatment for a rare heart disease, does not meet its primary goal. According to the sources, the trial evaluates whether the drug can outperform a placebo in improving patient outcomes. While AstraZeneca says the therapy is generally well tolerated, it does not show better results than placebo for the main measure of effectiveness.
One source describes the study outcome as a failure to reduce cardiovascular deaths or to lower the risk of recurring or subsequent heart-related problems. Another source emphasizes that, although the treatment’s safety profile is acceptable, it does not achieve the intended benefit in the trial’s primary endpoint. The drug is described as having been developed with Ionis, though the specific role of Ionis is not detailed in the excerpts.
Overall, the reports indicate that Wainua does not demonstrate the expected clinical advantage in this late-stage setting, despite acceptable tolerability. Additional analyses and next steps are not covered in the provided text.
